UnitedHealthcare Bariatric Surgery Policy Update | OpenPayer
ModifiedUnitedHealthcarePolicy CS007KY.11
Bariatric Surgery (for Kentucky Only)
UnitedHealthcare policy governing medical necessity, coverage rationale, definitions, and coding for bariatric and metabolic surgery services for members in Kentucky.
Policy Summary
PayerUnitedHealthcare
PolicyBariatric Surgery (for Kentucky Only)
Policy CodePolicy CS007KY.11
Change TypeRemoved 'proven and medically necessary' languageCPT 43999 added
Effective DateMay 1, 2025
Next Review Date
Key ActionUse InterQual criteria for medical necessity determinations and include multidisciplinary documentation with prior authorization requests.
Removed language indicating that multiple listed bariatric surgical procedures (including adjustable gastric band, biliopancreatic diversion with duodenal switch, RYGB, sleeve gastrectomy, revisional procedures, and band adjustments/removals) are proven and medically necessary.
Added CPT code 43999 to Applicable Codes.
Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.
Updated related policies link/title for 'Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Kentucky Only)'.
Kentucky-onlyGeographic applicability
InterQual referencedClinical criteria source
Unproven listUnproven procedures
6 months
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
IGB typical duration
12 monthsTPS approved duration
1CPT code added
Coverage Criteria and Clinical Rationale
Medical Necessity and Unproven Procedures
Coverage relies on InterQual clinical criteria; the policy also lists procedures considered unproven and not medically necessary.
InterQual-based medical necessity: Medical necessity determinations for bariatric and metabolic surgical procedures are based on the InterQual® CP: Procedures: Bariatric or Metabolic Surgery and Bariatric or Metabolic Surgery (Adolescent).
Refer to InterQual for specific inclusion/exclusion criteria.
Unproven / Not medically necessary procedures: The following procedures and device-based interventions are considered unproven and not medically necessary for treating obesity due to insufficient evidence of efficacy or safety: bariatric surgery as primary treatment for non-obesity conditions; bariatric artery embolization (BAE); gastric electrical stimulation with implantable gastric stimulator (IGS/GES); gastrointestinal liners (e.g., EndoBarrier/DJBL); intragastric balloon (IGB) therapies; laparoscopic greater curvature plication (total gastric vertical plication, LGCP); mini-gastric bypass/one-anastomosis gastric bypass (MGB/LMGB/OAGB); single-anastomosis duodenal switch/SIPS/SADI (single-anastomosis duodenal switch); stomach aspiration therapy (AspireAssist); transoral endoscopic procedures (including TransPyloric Shuttle® [TPS] and endoscopic sleeve gastroplasty [ESG]); and vagus nerve blocking (VBLOC).
Items explicitly listed as unproven in the policy.
Surgical Approaches and Indications (Descriptive)
Descriptions of common surgical approaches and their clinical goals to inform appropriate procedure selection.
Surgical goal: The primary goal of surgical treatment for obesity is to induce significant weight loss to reduce obesity-related comorbidities and improve quality of life; procedure choice is individualized based on patient assessment.
VSG reduces stomach volume and ghrelin production; LAGB uses an adjustable silicone band.
Malabsorptive and combined approaches: Malabsorptive procedures limit nutrient absorption (examples: Roux-en-Y gastric bypass [RYGB], biliopancreatic diversion with duodenal switch [BPD/DS]); some procedures combine restrictive and malabsorptive mechanisms and may be staged or performed laparoscopically or open.
BPD/DS creates intestinal limbs with a short common channel (≈50–100 cm) producing significant malabsorption.
Clinical evidence summaries
Summarized findings from systematic reviews, meta-analyses, randomized trials, and cohort studies that inform coverage decisions.
Short-term endoscopic efficacy: Systematic reviews and meta-analyses (e.g., Jung et al. 2020) show many endoscopic bariatric procedures achieve superior short-term weight loss compared with lifestyle modification, but long-term efficacy and safety data are limited.
22 studies / 2,141 patients included in Jung et al. 2020.
Long-term surgical outcomes: Long-term data (≥10 years) indicate substantial sustained weight loss after established surgical procedures (e.g., weighted mean %EWL ~56.7% for RYGB; ~74.1% for BPD/DS in selected reports), supporting durable benefit for select operations.10+ year follow-up reported
O'Brien et al. 2019 systematic review/meta-analysis.
Comparative effectiveness of RYGB vs SG: Randomized and observational studies indicate RYGB may produce greater early weight loss than sleeve gastrectomy at 2 years in some cohorts, with higher early complication rates for RYGB; overall mid-term equivalence is reported in several meta-analyses but longer-term differences remain uncertain.
Summary coverage logic from clinical evidence
Overall coverage logic derived from comparative effectiveness and long-term safety considerations.
Evidence-based comparative logic: High-quality randomized and systematic review evidence supports that bariatric surgery produces greater and more durable weight loss and comorbidity improvement than non-surgical care for appropriately selected patients; however evidence quality and long-term data vary by procedure type.
Cochrane and other systematic reviews summarize these findings.
Procedure-specific long-term concerns: Certain procedures (e.g., BPD/DS) offer greater long-term weight loss for very high BMI patients but carry higher long-term nutritional deficiency risk; procedures lacking robust long-term RCTs or with safety signals are considered investigational or limited pending further evidence.
Balance efficacy versus long-term complications informs coverage stance.
Investigational/device therapies: BAE, GES, IGB variants, and other emerging endoscopic/device therapies demonstrate short-term benefit in some trials but lack consistent long-term randomized evidence and have variable safety signals; these therapies are often considered investigational until more robust data are available.
IGB: efficacy, durability, safety
Evidence and limitations specific to intragastric balloon therapies (IGB).
Short-term efficacy of IGB: Randomized trials demonstrate clinically significant short-term total body weight loss while the balloon is in place (examples: Spatz trial mean %TBWL ~15.0% at ~32 weeks; REDUCE dual-balloon %EWL ~25.1% at 24 weeks), with IGB plus lifestyle outperforming lifestyle alone in pivotal RCTs.6 months (typical device duration) or 24 weeks endpoints met
REDUCE and Spatz RCTs reported significant short-term outcomes.
Durability concerns: Sustained weight loss beyond device removal is uncertain; many patients regain weight after balloon removal unless ongoing interventions (diet, behavioral, pharmacotherapy or repeat procedures) are undertaken.
Follow-up after removal shows weight regain in several studies.
Safety and tolerability: Adverse events reported across trials include nausea, early retrieval for intolerance, balloon deflation, gastric ulcers, and rare serious events; AE rates and device-specific risks vary by system and trial protocol.
Investigational therapies: BAE and GES
Summary of current evidence for bariatric artery embolization (BAE) and gastric electrical stimulation (GES).
Bariatric artery embolization (BAE): Small randomized and case-series data show modest short-term weight loss after left gastric artery embolization, but sample sizes, heterogeneous techniques, and variable follow-up limit conclusions; BAE is considered investigational pending larger RCTs with long-term outcomes.6–12 month follow-up commonly reported
Reddy et al. 2020 sham-controlled RCT showed greater TBWL at 6 months but long-term significance unclear.
Gastric electrical stimulation (GES): GES/implantable gastric stimulators demonstrated variable weight-loss results in small feasibility studies and cohorts; predictors of response have been suggested, but definitive large RCTs with long-term follow-up are lacking, so GES remains investigational for obesity treatment.
Systematic reviews and small multicenter prospective studies report mixed durability and safety.
LGCP: limited evidence and durability concerns
Evidence limitations and observed outcomes for laparoscopic greater curvature plication (LGCP).
LGCP outcomes and durability concerns: LGCP series report initial weight loss but limited long-term durability with substantial weight regain in some cohorts and a notable reoperation rate (example: single-center series reported 13/75 revisions), indicating insufficient evidence to support LGCP as equivalent to sleeve gastrectomy.5-year follow-up indicates weight regain in reported series
Evidence primarily from retrospective series; randomized data lacking.
Coverage stance by procedure/device
Coverage considerations vary by procedure/device based on the balance of efficacy, durability, and safety evidence.
IGB—short-term positive, long-term uncertain: IGB systems demonstrate statistically significant short-term weight loss compared with diet/exercise in RCTs (e.g., REDUCE, Spatz), but long-term durability after device removal is uncertain, necessitating counseling and documented follow-up plans when considered for coverage.24–32 week controlled endpoints in pivotal trials
Pivotal RCTs reported co-primary endpoints met but recommend longer follow-up studies.
LGCP—insufficient comparative durability: LGCP shows variable long-term outcomes and higher revision or weight-regain rates in some series compared with LSG, supporting an investigational or limited coverage stance until robust long-term comparative data are available.5-year series show weight regain and revisions
General coverage determination for emerging endoscopic and device-based bariatric procedures
Overall coverage determination for emerging endoscopic and device-based bariatric procedures.
Investigational or insufficient evidence stance: Emerging endoscopic and device-based bariatric therapies generally lack robust long-term randomized controlled trial evidence for sustained safety and effectiveness; therefore they are considered investigational or limited to research/special arrangements pending stronger evidence.
Covered when ALL of the following are met for endoscopic intragastric balloon (IGB) therapy.
Patient selection: Patient has obesity and has failed conventional weight‑loss strategies (supervised diet, exercise, behavioral modification, with or without pharmacotherapy) and is being considered for temporary endoscopic intragastric balloon therapy as an adjunct to a multidisciplinary weight‑management program.
AGA and ASGE guidance support IGB use in patients who have failed conventional strategies; device labeling (e.g., ORBERA) specifies BMI and program requirements.
Device regulatory and duration limits: The planned intragastric balloon is an FDA‑cleared device used within its labeled indication and maximum in‑situ duration (for example, ORBERA indicated for adults with BMI ≥30 and ≤40 kg/m2 for up to six months), and the treatment plan documents scheduled removal within the approved timeframe.max 6 months in situ for many FDA‑approved balloons
Refer to FDA device labeling and ASMBS/AGA recommendations.
Covered only with careful selection and documentation of risks and expected benefits for duodenal-jejunal bypass sleeve (DJBL/EndoBarrier).
Conditional use and research preference: Use of duodenal‑jejunal bypass liner (EndoBarrier/DJBL) should be limited to carefully selected patients, preferably within clinical research protocols or special arrangements, given limited quality evidence and notable safety concerns including hepatic abscess and gastrointestinal hemorrhage.
NICE recommends DJBL use only in research; significant adverse events and high explantation rates reported.
Patient selection and predictive factors: When considered, document factors associated with higher chance of benefit (as reported in retrospective series), for example higher C‑peptide (≥1.0 nmol/L) and greater body weight (≥107 kg) were associated with improved response in one cohort; clearly document anticipated benefit and alternative options.C‑peptide ≥1.0 nmol/L and weight ≥107 kg may predict success per retrospective analysis
Betzel et al. reported these predictive factors but evidence remains limited.
Risk–benefit and monitoring plan:
General coverage criteria for bariatric procedures
Covered when ALL of the following are met for selected bariatric procedures supported by guideline endorsement and evidence.
Established evidence of durable efficacy and safety: Procedure has substantial peer‑reviewed long‑term outcome data demonstrating durable weight loss and comorbidity improvement (examples: sleeve gastrectomy and Roux‑en‑Y gastric bypass as described in guideline summaries).long‑term outcomes documented
SG and RYGB have substantial long‑term evidence and guideline endorsement.
Multidisciplinary preoperative evaluation: Patient has been evaluated and approved by a comprehensive multidisciplinary bariatric program that provides surgical assessment, nutritional and psychosocial evaluation, and long‑term follow‑up capability.documentation of multidisciplinary evaluation
ASMBS and other society guidance require multidisciplinary assessment.
Adolescent criteria where applicable:
Procedures with limited evidence / research-only recommendations
Procedures with limited evidence or recommended only in research or special arrangements.
Temporary intragastric balloon (IGB): IGB is an FDA‑approved, temporary therapy (commonly up to six months) that can be considered within its labeled indications and with documented multidisciplinary follow‑up; outside labeled use or prolonged implantation without clear follow‑up may be inappropriate.max 6 months per FDA labeling for ORBERA
ASMBS statements and FDA labeling emphasize temporary use and programmatic follow‑up.
EndoBarrier / DJBL: Duodenal‑jejunal bypass liner (EndoBarrier) evidence is limited and associated with notable adverse events; NICE recommends its use only in research and the device lacks a current CE mark, supporting research‑only or special‑arrangement use.
NICE IPG and other reviews advise research‑context use.
SADI‑S / SADS: Single‑anastomosis duodenal‑ileal switch (SADI‑S/SADS) and related hypoabsorptive variants have limited high‑quality evidence and are recommended by NICE to be performed only with special arrangements for governance, consent, audit, or research until more robust data are available.
Revisional bariatric surgery
Revisional bariatric surgery coverage considerations and required evaluation.
Indications for revisional surgery: Revisional bariatric surgery may be considered for persistent or progressive obesity, unresolved comorbidity, complications of an index procedure, or intolerable side effects after thorough multidisciplinary evaluation documenting the probable anatomic or physiologic cause and rationale for reoperation.
ASMBS Revision Task Force supports careful selection and evaluation prior to reoperation.
Risk and selection factors: Because reoperative procedures carry higher risk, coverage decisions should consider prior procedure type, patient anatomy, surgeon expertise, relative risks/benefits, and documented non‑surgical contributors to inadequate weight loss or weight regain.
Reoperation rates and outcomes summarized in ASMBS reviews; multidisciplinary assessment required.
Eligibility and evidence-aligned use
Eligibility and evidence-aligned use: procedures and devices supported when guideline and device-specific criteria are met.
Core BMI and guideline thresholds: Patient meets BMI criteria per applicable device labeling or clinical guideline (examples include NICE: BMI ≥40 kg/m² or 35–39.9 kg/m² with a significant health condition; ORBERA IGB FDA indication: BMI ≥30 and ≤40 kg/m²), with lower BMI thresholds considered for certain ethnic groups per guideline recommendations.see device labeling and guideline thresholds
NICE, FDA, and other society thresholds referenced in policy.
Documented conservative management: Documented attempt and inadequate response to supervised diet, exercise, and behavioral modification (and pharmacotherapy where applicable) should be provided when required by device labeling or guideline recommendations prior to surgery or device implantation.prior conservative therapy documented where indicated
Guidelines and trial inclusion criteria commonly require prior conservative therapy.
The policy clarifies that bariatric surgery should not be performed as the primary treatment for any condition other than obesity. It explicitly lists a set of interventions that are considered unproven and not medically necessary for treating obesity due to insufficient evidence of efficacy, including but not limited to: bariatric artery embolization (BAE), gastric electrical stimulation with an implantable gastric stimulator (IGS), gastrointestinal liners, intragastric balloon, laparoscopic greater curvature plication (total gastric vertical plication), mini‑gastric bypass/one‑anastomosis gastric bypass (MGB/LMGBP/OAGB), single‑anastomosis duodenal switch (SIPS/SADS), stomach aspiration therapy (AspireAssist®), transoral endoscopic surgery (including TPS and endoscopic sleeve gastroplasty), and vagus nerve blocking (VBLOC®).
The duodenal‑jejunal bypass liner (EndoBarrier™) is not FDA‑approved for use in the United States and, under federal law, is limited to investigational use only. This regulatory status is a basis for restricting routine coverage and indicates use should be limited to approved research contexts.
Bariatric artery embolization (BAE) is considered investigational. Available evidence is limited to small case series and a single small sham‑controlled RCT with short follow‑up; overall data are insufficient to establish long‑term effectiveness or safety for routine management of obesity.
Gastric electrical stimulation (GES) remains investigational pending larger, well‑designed randomized controlled trials with long‑term follow‑up. Early feasibility studies and systematic reviews report variable short‑term weight loss but lack durable, controlled evidence to confirm safety and efficacy for obesity treatment.
Laparoscopic greater curvature plication (LGCP) may be excluded or considered investigational when presented as an alternative to laparoscopic sleeve gastrectomy (LSG). Comparative data and pooled analyses show LGCP provides inferior weight‑loss outcomes and a higher rate of adverse events and revisions versus LSG in longer‑term follow‑up, supporting a noncoverage stance outside of research or specialized protocols.
Several devices and procedures are considered to have insufficient evidence to support routine coverage. Examples include stomach aspiration therapy (AspireAssist), the TransPyloric Shuttle (TPS) and other transoral endoscopic bypass devices, certain transoral endoscopic procedures and swallowable balloons, endoscopic sleeve gastroplasty (ESG) as an emerging technology, and neuromodulation approaches (vBloc) where pivotal endpoints were not clearly met. These modalities require additional high‑quality RCTs and longer‑term safety data before being considered medically necessary for routine obesity treatment.
The policy states that use of devices or procedures beyond their approved indications, or prolonged implantation without documented follow‑up and timely removal, may be excluded due to safety concerns. For temporary devices (for example, intragastric balloons), the policy emphasizes adherence to labeled maximum in‑situ durations and documented plans for removal and follow‑up to mitigate risk.
The policy does not enumerate absolute exclusions in this section, but references society guidance noting relative contraindications that may prompt denial or further review. Examples include severe heart failure, unstable coronary artery disease, end‑stage lung disease, active cancer treatment, cirrhosis with portal hypertension, uncontrolled substance dependence, and severely impaired intellectual capacity. The Endocrine Society additionally advises against bariatric surgery in preadolescent children, pregnant or breastfeeding adolescents, or patients with unresolved substance use or untreated psychiatric disorders.
Because of limited and inconsistent safety and efficacy data, use of the duodenal‑jejunal bypass liner (EndoBarrier) is recommended only in the context of research. Published trials report meaningful weight loss while the device is in place but also high rates of adverse events (including hepatic abscess and gastrointestinal hemorrhage) and frequent weight regain after removal, supporting research‑only use.
Effective 05/01/2025, the policy removed prior wording that had specifically listed several bariatric surgical procedures as "proven and medically necessary." That operational change means those procedures are no longer presented in the policy text as automatically proven/medically necessary and coverage decisions should follow the updated criteria and evidence summaries.
The policy explicitly states that the procedures and devices listed as unproven in the coverage rationale are considered not medically necessary for treating obesity due to insufficient evidence of durable benefit and safety. Providers should anticipate coverage denial for these interventions when proposed for routine treatment of obesity outside approved indications or research protocols.
Evidence for intragastric balloons (IGBs) demonstrates clinically significant short‑term weight loss while the device is in place, but the literature shows mixed results for long‑term durability after removal and variable safety profiles across devices. FDA‑approved balloons are temporary (commonly up to six months) and require multidisciplinary follow‑up; routine use without clear indication, adherence to labeled in‑situ duration, and structured follow‑up is limited by the current evidence base.
Several procedures and device techniques are deemed to have insufficient long‑term evidence to support routine coverage. Examples include one‑anastomosis/mini‑gastric bypass (OAGB/MGB) beyond five years where long‑term safety and nutritional outcomes remain uncertain, single‑anastomosis duodenal switch variants (SADI/SADS/SADIS) lacking robust RCT data with long‑term follow‑up, and other hypoabsorptive or novel procedures where late nutritional complications or GERD have been reported.
The policy reiterates that stomach aspiration therapy, TPS, certain transoral endoscopic devices, and endoscopic sleeve gastroplasty lack adequate long‑term evidence of safety and effectiveness. Given current data limitations and variable adverse event profiles, these therapies are considered investigational or not medically necessary for routine coverage outside clinical trials.
Use of the duodenal‑jejunal bypass sleeve (DJBS/EndoBarrier) may be considered not medically necessary for routine clinical use where high‑quality RCT evidence demonstrating long‑term efficacy and safety is lacking. NICE and other guidance recommend that the device be used only within research settings or with appropriate governance, given concerns about adverse events and weight regain after explantation.
Both EndoBarrier and swallowable gastric balloons lack adequate high‑quality evidence to support routine clinical use. Consistent with NICE guidance, these devices are advised to be performed only in research settings until further evidence from robust randomized trials and longer‑term safety data become available.
Swallowable gastric balloons and certain endoscopic bariatric devices do not yet have sufficient evidence of efficacy and safety for routine coverage; NICE guidance recommends that these technologies be confined to research contexts until stronger evidence accrues.
Applicable Codes and Coding Guidance
Intragastric balloon endoscopy codesCPT
0813T
Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
43290
Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon
Covered/Applicable CPT codes (partial list)CPT
43291
Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
43644
Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
43645
Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption.
43647
Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648
Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659
Unlisted laparoscopy procedure, stomach.
43770
Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only.
1–10 of 13
1/2
Additional applicable CPT codes (partial list)CPT
43845
Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (biliopancreatic diversion with duodenal switch).
43846
Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy.
43847
Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption.
43848
Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device.
43860
Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy.
43865
Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; with vagotomy.
43881
Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882
Revision or removal of gastric neurostimulator electrodes, antrum, open.
43886
Gastric restrictive procedure, open; revision of subcutaneous port component only.
43887
Gastric restrictive procedure, open; removal of subcutaneous port component only.
1–10 of 15
1/2
Device/procedure codes discussed in narrativemixed
No codes listed
Applicable CPT Codes (added)CPT
43999
Unlisted procedure, stomach
inv-38: BMI — obesity defined by BMI and adult categories
BMI definitionWeight in kilograms divided by the square of height in meters (Body Mass Index, BMI).
Adult BMI categories (NHLBI)<18.5 underweight; 18.5–24.9 normal; 25–29.9 overweight; 30–34.9 Obesity Class I; 35–39.9 Obesity Class II; ≥40 Obesity Class III.
Use of BMIBMI is used as a screening tool but is not diagnostic of body fatness or overall health; used to determine eligibility for obesity therapies.
Common trial inclusion BMIMany pivotal intragastric balloon RCTs enrolled adults with BMI ≥30 kg/m² (e.g., Spatz, REDUCE trials).
Prior Authorization, Documentation, and Provider Requirements
Prior Authorization
Prior Authorization Required
Prior authorization is typically required for bariatric procedures and endoscopic bariatric devices. The request must specify the planned procedure or device, intended duration of device use (e.g., intragastric balloon placement period, typically up to six months per FDA/ASMBS guidance), and include evidence of a multidisciplinary pre-procedure evaluation. UnitedHealthcare may reference InterQual® criteria when making medical necessity determinations.
Prior authorization must capture planned procedure and device duration (e.g., IGB maximum placement ~6 months per FDA/ASMBS).
InterQual® may be used as the primary clinical criteria source for determinations.
Intragastric balloon (IGB) prior authorization requests must document BMI eligibility, failed conservative non-surgical weight-loss attempts, enrollment in or plan for concomitant lifestyle/behavioral interventions, and planned device duration/ removal timing. Include perioperative care plans (e.g., PPI prophylaxis, antiemetic strategy) and follow-up arrangements to monitor for intolerance, deflation, or early retrieval.
Clinical Background and Evidence Context
Obesity is defined clinically using Body Mass Index (BMI) and is associated with multiple medical comorbidities, including hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, obstructive sleep apnea, and certain cancers. Screening and referral to intensive behavioral interventions are recommended for individuals with BMI ≥30 kg/m², and metabolic/bariatric surgery is intended to produce substantial, durable weight loss to reduce obesity‑related morbidity when conservative measures have failed.
Definitions and Abbreviations
inv-81: Body Mass Index (BMI) definition and usage
BMI formulaBMI = weight (kg) divided by height (m) squared.
Screening roleBMI is a screening tool; USPSTF recommends screening adults and referring those with BMI ≥30 kg/m² to intensive behavioral interventions.
Not diagnostic aloneBMI alone does not diagnose body fatness or health status; clinical context and comorbidities must be considered.
Removed prior language that listed multiple specific bariatric surgical procedures as 'proven and medically necessary' from the Coverage Rationale.
2025-05-01coding_updateLatest
Added CPT code 43999 (Unlisted procedure, stomach) to the Applicable Codes section.
The policy update summarizes several changes: removal of prior language that had listed specific bariatric procedures as "proven and medically necessary" (effective 05/01/2025), addition of CPT code 43999 to the applicable codes list, and non‑material updates to the description of services, clinical evidence, and references. These edits clarify the policy’s emphasis on evidence‑based coverage determinations and the use of InterQual criteria for medical necessity assessments.
Policy Summary
PayerUnitedHealthcare
PolicyBariatric Surgery (for Kentucky Only)
Policy CodePolicy CS007KY.11
Change TypeRemoved 'proven and medically necessary' languageCPT 43999 added
Effective DateMay 1, 2025
Next Review Date
Key ActionUse InterQual criteria for medical necessity determinations and include multidisciplinary documentation with prior authorization requests.
Quality of life and comorbidity improvements: Meta-analyses report improvements in health-related quality of life and sleep parameters after bariatric surgery, although many studies lack non-surgical comparison groups and long-term follow-up.
Magallares et al. 2015; Xie et al. 2016.
Multiple systematic reviews and small RCTs inform this conclusion.
Device-specific trial reports and ASMBS/AGA guidance highlight safety considerations.
MGB/OAGB and SADI/SADI-S:
Mini-gastric/one-anastomosis and single-anastomosis duodenal switch variants demonstrate promising mid-term weight loss but have potential for increased GERD, malabsorption, and nutritional complications; limited long-term (>5 year) RCT evidence warrants careful selection and monitoring if used.
Higher GERD incidence and malabsorption risks reported
Observational cohorts and limited RCT data inform this position.
Aspiration therapy—limited long-term evidence: Aspiration therapy (AspireAssist) showed improved weight loss maintained up to 4 years in low-quality studies with pooled SAE ~4.1%; evidence is insufficiently robust for routine broad coverage without further RCTs and safety monitoring.~18.6% TBWL at 4 years in limited-quality data
Systematic reviews reported maintenance but with low-quality evidence.
Documented multidisciplinary program and plan for nutritional, behavioral, and medical follow‑up during implantation and after removal, including PPI prophylaxis and antiemetic management as indicated.
AGA recommends concomitant lifestyle modification and PPI prophylaxis for IGB therapy.
Informed consent and risk counseling: Patient provided informed consent that includes discussion of common peri‑procedural intolerance symptoms, potential device‑related adverse events (e.g., deflation, ulceration), likelihood of weight regain without ongoing interventions, and alternatives including surgical options.
ASMBS and device trial protocols emphasize informed consent and counseling about risks and durability.
Obtain detailed informed consent describing the frequency and severity of adverse events, ensure plans for close monitoring, prompt device removal if complications occur, and document rationale for use over other options.
High AE frequency and early explantation observed in DJBL series; document monitoring plan.
For pediatric/adolescent candidates, meet recognized adolescent-specific eligibility criteria (examples: BMI ≥120% of the 95th percentile with comorbidity or ≥140% of the 95th percentile, or other guideline thresholds) and demonstrate family stability and readiness for long‑term follow‑up.
BMI ≥120% of 95th percentile with comorbidity or ≥140% of 95th percentile; Tanner and psychosocial considerations per Endocrine Society/ASMBS
Follow pediatric/adolescent society guidance for selection and evaluation.
NICE interventional procedure guidance recommends special arrangements or research use.
Multidisciplinary care and follow‑up plan:
Patient is willing to engage in long‑term multidisciplinary follow‑up for nutritional monitoring, behavioral support, and medical surveillance post‑procedure or device removal.
ongoing follow‑up plan documented
Society guidelines emphasize long‑term follow‑up capability.
Investigational/research‑only procedures: Procedures or devices identified as investigational (e.g., EndoBarrier/DJBL, swallowable gastric balloons, some ESG platforms in evolving evidence contexts, SADI‑S under special arrangements) should be performed only under approved research protocols or special governance arrangements until stronger evidence is available.enrollment in approved research protocol or special governance
NICE interventional guidance and policy text support research‑only use for these technologies.
Adjustable balloon trial exampleSpatz RCT included participants with BMI ≥30 kg/m² and documented unsuccessful non-surgical weight-loss attempts.
Dual-balloon REDUCE trial exampleREDUCE enrolled participants with BMI 30–40 kg/m² (mean BMI ~35.4) and reported significant short-term weight loss at 24–32 weeks.
inv-40: BMI thresholds for metabolic/bariatric surgery — common thresholds (≥40; ≥35 with comorbidity; consideration for 30–34.9 with T2D)
Primary surgical thresholds (AACE/ASMBS)MBS recommended for BMI ≥35 kg/m²; considered for BMI 30–34.9 kg/m² in presence of metabolic disease (ASMBS/IFSO update).
Class III surgery thresholdBMI ≥40 kg/m² is an indication for metabolic/bariatric surgery regardless of comorbidities (AACE/ASMBS/ADA statements).
Device-specific lower threshold for some devicesORBERA IGB FDA indication: adults with BMI ≥30 and ≤40 kg/m² for up to six months (FDA ORBERA PMA).
inv-41: Adolescent BMI thresholds — pediatric thresholds per specialty societies
ASMBS pediatric thresholdsAdolescents: Class II obesity = ≥120% of the 95th percentile for age (or BMI 35–39.9 kg/m²); Class III = ≥140% of the 95th percentile (or BMI ≥40 kg/m²).
AAP surgical guidance (age ≥12)AAP recommends MBS for adolescents ≥12 with Class II (BMI ≥35 or 120% of 95th percentile) with clinically significant disease, or Class III (BMI ≥40 or 140% of 95th percentile).
Endocrine Society pubertal criteriaEndocrine Society suggests bariatric surgery in Tanner stage 4–5 adolescents meeting BMI criteria and with appropriate comorbidities and psychosocial assessment.
inv-42: BMI thresholds and related mentions — NICE thresholds and ethnicity adjustments
NICE adult thresholdsNICE: consider bariatric surgery for BMI ≥40 kg/m² or BMI 35–39.9 kg/m² with a significant health condition; expedited consideration when recent‑onset T2D (within 10 years).
Ethnicity adjustmentNICE and professional statements recommend lowering BMI thresholds by ~2.5 kg/m² for South Asian, Chinese, other Asian, Middle Eastern, Black African or African‑Caribbean backgrounds due to higher cardiometabolic risk at lower BMI.
Device and guideline concordanceGuidelines and device labels (e.g., ORBERA) specify BMI ranges and may differ; verify device indication and guideline-recommended thresholds for individual cases.
Document BMI and duration of obesity; evidence of failed supervised diet/exercise/behavioral therapy.
Specify planned IGB duration (FDA/ASMBS standard: up to 6 months) and removal plan.
Include plan for concomitant moderate- to high-intensity lifestyle modification and PPI prophylaxis where indicated.
Documentation Required
Procedures/Devices with Limited Long-Term Evidence
For procedures and devices with limited long-term evidence (eg, ESG, transoral devices, gastrointestinal liners, single-anastomosis duodenal-ileal switch, mini-gastric/one-anastomosis gastric bypass, aspiration therapy), prior authorization should include detailed supporting evidence, rationale for device/procedure selection over established alternatives, and plans for long-term follow-up. UnitedHealthcare may require additional documentation or may deny requests when evidence is insufficient.
Provide study data or rationale showing expected benefit over standard care, and a plan for long-term outcome monitoring.
Expectation of multidisciplinary evaluation and justification when selecting less-established therapies.
Documentation Required
Center Referral and Multidisciplinary Evaluation
Referral to an accredited comprehensive metabolic and bariatric surgery center (eg, MBSAQIP-accredited) is expected when applicable. Prior authorization requests for surgical or complex endoscopic interventions should include evidence of multidisciplinary evaluation (surgical, medical, nutritional, and behavioral health), documentation of center accreditation where available, and a care plan for perioperative and long-term follow-up.
Include documentation of multidisciplinary team assessment (medical, nutrition, behavioral health, surgical).
Include center accreditation status (MBSAQIP) when available.
Documentation Required
Confirm Regulatory and Evidence Status
Confirm the device or procedure's regulatory status and labeled indications (FDA approvals/cleared indications, CE status, or investigational status). Prior authorization must note whether the intended use aligns with FDA labeling or is investigational/off-label; coverage decisions will consider regulatory status and the available evidence.
Refer to FDA PMA/510(k) documentation when applicable (eg, ORBERA IGB PMA details).
If device/procedure is outside FDA labeling or lacks regulatory clearance, indicate whether use is in a research/clinical trial setting.
Billing Rule
Coding Documentation and Updates
Coding and billing must follow policy guidance. Use specified CPT codes for reporting procedures and devices; note that CPT 43775 is preferred for laparoscopic sleeve gastrectomy rather than unlisted 43659. CPT 43999 has been added for use where applicable per UnitedHealthcare updates.
Report laparoscopic sleeve gastrectomy with CPT 43775 per coding clarification.
Use listed CPTs for intragastric balloon placement/removal (e.g., 43290, 43291, 0813T) and consider CPT 43999 where indicated.
Inclusion of a code in the policy is for reference and does not guarantee coverage; follow federal/state/contractual requirements.
Prior Authorization
Revisional Surgery Assessment and Documentation
Revisional bariatric surgery prior authorization must include a comprehensive multidisciplinary assessment, documentation of the anatomic or behavioral cause of inadequate weight loss or complications, prior conservative management (including GERD treatments where relevant), and suitability for revision. Lack of multidisciplinary evaluation or failure to document etiology may lead to denial or additional review.
Document prior evaluation to determine whether weight regain is due to anatomic failure versus behavioral factors.
For GERD after bariatric surgery, document trials of lifestyle modification and acid-reducing medications before revisional procedures.
Denial Risk
Device-Related Complications Affecting Coverage
Device-related complications (eg, early retrieval, spontaneous deflation, ulceration, migratory events, hepatic abscess with DJBL) should be explicitly documented in authorization and subsequent claims as they may affect coverage decisions. Prior adverse events or complications can change appropriateness for reimplantation or further device-based therapy.
Include device complication history (deflation, migration, ulcers, liver abscess, hemorrhage) and treatments rendered.
Detail plans to mitigate recurrence and rationale if considering repeat device therapy.
Denial Risk
Evidence Insufficiency and Denial Risk
Insufficient or conflicting evidence for a procedure/device may trigger denial or requirement for additional documentation. Examples include intragastric balloons for long-term chronic weight management, gastrointestinal liners (EndoBarrier/DJBL), transoral devices, ESG, SADIS/SADI, and aspiration therapy. When evidence is limited, coverage may be restricted to research settings or denied.
If the device/procedure is considered investigational or evidence is inconclusive, include clinical trial enrollment details if applicable.
UnitedHealthcare may restrict use to clinical investigations or deny coverage when evidence does not support safety/efficacy.
Documentation Required
Limited or Inconclusive Evidence — Authorization Expectations
Some devices/procedures have limited or inconclusive evidence even when short-term outcomes appear promising (eg, transoral devices, ESG, liners). Prior authorization should include RCT evidence where available, long-term outcome data, and a plan for post-procedure follow-up. Lack of confirmatory studies or long-term data increases the likelihood of denial.
Provide randomized controlled trial data and long-term follow-up when available.
Document the expected duration of benefit and monitoring plan for late complications.
Denial Risk
Safety-Related Denial Risk for DJBL
The duodenal-jejunal bypass liner (DJBL/EndoBarrier) has been associated with higher rates of serious adverse events (hepatic abscess, GI hemorrhage, obstruction) and frequent explantation; these safety concerns may prompt denial or strict use limitations. Authorization for DJBL should include risk assessment and detailed monitoring plans.
Document history of prior DJBL use and any serious AEs (eg, hepatic abscess).
Provide rationale and mitigation strategies if considering similar gastrointestinal liner therapies.
Denial Risk
Relative Contraindications and Additional Review
Relative contraindications (eg, severe heart failure, unstable coronary disease, end-stage lung disease, active cancer treatment, portal hypertensive cirrhosis, uncontrolled substance use, severe cognitive impairment) should be screened and documented. Presence of such conditions may prompt denial or require additional review.
List relevant relative contraindications and document clinical reasoning if proceeding despite relative risks.
Provide additional specialist consultations or clearance as requested.
Note
Conflicts with Contractual/State Requirements
Coverage decisions must align with federal, state, and contractual benefit requirements. When conflicts exist between this policy and plan-specific or jurisdictional mandates, the federal/state/contractual terms govern.
Before finalizing authorization, verify applicable federal, state, and contractual coverage mandates.
UnitedHealthcare reserves the right to apply InterQual®, UHC policies, or other criteria when InterQual® is not applicable.
Documentation Required
Required Clinical Documentation for Device Trials
Authorization requests for device trials or investigational use must provide the trial protocol, inclusion/exclusion criteria, BMI and prior unsuccessful non-surgical weight-loss documentation, and planned outcome assessments (eg, %TBWL, %EWL) and follow-up schedule. If use is within a clinical trial, attach IRB approval and monitoring plans.
Include BMI, documented failed conservative therapy, and trial-specific endpoints and follow-up timelines.
Attach trial documents (protocol, IRB approval) when applicable.
Documentation Required
Recommended Supporting Documentation
Support authorization with high-quality documentation: RCT data where available, systematic reviews, guideline endorsements (ASGE/ASMBS/AGA/AACE), and rationale for choosing the procedure/device over standard options. Document prior conservative management, multidisciplinary evaluations, and informed consent elements.
Cite pivotal RCTs, meta-analyses, or guideline statements supporting use.
Provide documentation of prior conservative weight-loss attempts and multidisciplinary team input.
Documentation Required
Preoperative Evaluation Documentation
Preoperative evaluation documentation should include an obesity-focused history, physical exam, relevant labs and diagnostics, detailed weight-loss history, and documentation of prior supervised weight-loss attempts. Note that mandatory preoperative weight loss is not uniformly supported; evaluate patients based on BMI, comorbidities, and individualized risk-benefit assessment.
Document weight history, prior programs, greatest duration of weight loss and maintenance.
Include pertinent labs/diagnostics and rationale for proceeding to intervention.
Documentation Required
Informed Consent and Psychosocial Evaluation
Obtain informed consent that discusses expected benefits, common and serious adverse events (including early intolerance, nausea, ulceration, device migration/deflation), need for adherence to lifestyle changes, and the possibility of weight regain after device removal. Include psychosocial evaluation and link to ongoing behavioral health support as part of the care plan.
Document that informed consent discussed risks (eg, device complications) and the need for multidisciplinary follow-up.
Include psychosocial assessment by a clinician experienced in bariatric care.
Step Therapy
Conservative and Stepwise Care Expectations
Conservative therapy (diet, activity, behavioral counseling, pharmacotherapy where appropriate) is expected before many surgical interventions. For device-based therapies, documentation of prior weight-loss attempts is generally required; for adolescents, prior attempts should be documented but not necessarily an absolute barrier to surgery.
Document supervised diet/exercise and behavioral interventions and any pharmacologic weight-loss trials.
For adolescents, include family assessment and documentation of counseling and support services.
OSA severeAHI or RDI >30 events/hour.
inv-83: Revisional Bariatric Surgery types — conversion, corrective, reversal
ConversionA second bariatric procedure that changes the approach to a different procedure type (e.g., band to RYGB).
CorrectiveA procedure that corrects or modifies anatomy of a prior bariatric procedure to achieve the original desired outcome or address a complication (e.g., pouch resizing).
ReversalA procedure that restores original anatomy after a prior bariatric operation.
inv-84: Biliopancreatic Diversion with Duodenal Switch (BPD/DS) definition
Procedure descriptionBiliopancreatic diversion with duodenal switch (BPD/DS) is primarily malabsorptive, includes resection of the greater curvature, and creates intestinal limbs that meet in a common channel of ~50–100 cm to limit absorption.
Long-term outcomes noteBPD/DS is associated with substantial long-term weight loss but notable long-term nutritional deficiencies and complication concerns; long-term follow-up data exist (e.g., 9-year series).
Common channel lengthTypical common channel length reported: 50–100 cm (limits absorption).
Procedure definitionLaparoscopic greater curvature plication (LGCP) is a restrictive operation that folds and sutures the greater curvature of the stomach to reduce gastric volume without resection or implant.
Alternative nameAlso known as Total Gastric Vertical Plication (TGVP).
Evidence/durability concernLimited RCT data and some series report high revision rates and weight regain over time; long-term durability is uncertain.
Procedure descriptionEndoscopic sleeve gastroplasty (ESG) is a transoral endoscopic suturing procedure (e.g., OverStitch) that reduces gastric capacity by creating a tube-shaped stomach without tissue resection.
Clinical evidenceRandomized and observational data demonstrate greater weight loss than lifestyle modification but long-term efficacy versus surgical sleeve remains uncertain.
Adverse eventsReported AEs include GI symptoms; rare serious AEs (e.g., abscess, bleeding, malnutrition) have been reported in trials.
inv-87: Intragastric Balloon (IGB) — definition and typical duration
IGB descriptionIntragastric balloons (IGB) are acid-resistant balloons inserted endoscopically or ingested and expanded with saline or air to occupy gastric volume and induce early satiety.
Typical durationStandard therapy duration is approximately six months (maximum six months for FDA‑approved ORBERA).
Adjunctive useIGBs are intended as adjuncts to diet, exercise, and behavioral counseling and require multidisciplinary follow-up for safety and weight‑maintenance planning.
inv-88: BPD/DS further definition and long-term outcome note
Long-term outcome noteBPD/DS yields substantial sustained weight loss in long-term cohorts but is associated with higher rates of nutritional deficiencies and requires careful long‑term monitoring.
Comparative safetyCompared with SG, BPD/DS may have similar early complication rates but greater long‑term nutritional risk; SG associated with fewer deficiencies in some reports.
Evidence lengthExamples include series with follow-up up to nine years documenting durable weight loss and nutritional problems in a notable proportion of patients.
DefinitionBariatric artery embolization (BAE) is endovascular embolization targeting gastric arteries (commonly the left gastric artery) intended to reduce ghrelin‑producing tissue and induce weight loss.
Evidence statusEvidence is limited; small RCTs and case series show modest short-term weight loss but insufficient robust long-term RCT data to establish efficacy and safety.
Reported AEsReports include transient mucosal ulcers and rare major complications (e.g., pancreatitis, splenic infarct, gastric perforation) in case series.
DefinitionGastric Electrical Stimulation (GES) comprises implantable or closed-loop electrical stimulation devices targeting the stomach to modulate appetite, motility, or satiety.
RCT/outcome noteSmall feasibility and cohort studies report variable weight‑loss outcomes; some trials show modest benefit but larger randomized long‑term studies are needed.
Safety profileReported device‑related AEs include implant site pain and procedural complications; serious AE rates vary across studies (e.g., ~4.3% primary related SAE in vBloc ReCharge reports).
Endoscopic or ingestible balloonsIGBs include endoscopically placed systems (e.g., ORBERA) and ingestible/swallowable balloons; all aim to occupy gastric volume to induce satiety and weight loss.
Temporary natureThese balloons are temporary devices with recommended in‑situ durations (commonly up to six months for FDA‑approved systems).
Evidence and guidanceASGE and ASGE/ASMBS reviews report pooled efficacy meeting PIVI thresholds for Orbera (e.g., ~13% TWL at 6 months; ~25% EWL at 12 months).
LGCP technical detailLGCP folds and sutures the greater curvature of the stomach to reduce gastric volume without resection, creating a restrictive effect similar to sleeve gastrectomy but without tissue removal.
Device/technique noteLGCP does not use an implantable device; it is a purely surgical plication technique performed laparoscopically.
Durability concernSome series report weight regain and high revisional surgery rates over five years, indicating uncertain long‑term durability.
inv-93: Abbreviations list for section (IGB, OAGB, SADS/SADI, AspireAssist)
DefinitionStomach aspiration therapy (AspireAssist) is an endoscopic gastrostomy‑based device that permits aspiration of gastric contents after meals to reduce caloric absorption.
Outcomes noteSystematic reviews/single‑arm studies report significant short‑term weight loss with some maintenance up to four years (~18.6% TWL in limited data), but evidence quality is low and AEs occur (pooled SAE ~4.1%).
Evidence statusInsufficient high‑quality RCT evidence for broad adoption; additional robust trials and long‑term safety data are needed.
inv-95: Transpyloric Shuttle (TPS) and transoral bypass devices — definition and limited evidence note
Transpyloric Shuttle (TPS) definitionTPS is a non‑balloon, space‑occupying endoscopic device consisting of a spherical and cylindrical silicone bulb connected by a tether, intended for up to 12 months of therapy and delivered/removed endoscopically.
Transoral bypass devicesTransoral endoscopic bypass devices are intraluminal implants delivered endoscopically to alter gastric emptying or nutrient flow; evidence limited to small feasibility studies and short follow-up.
Regulatory noteTPS received FDA premarket approval for up to 12 months in specified BMI ranges; longer‑term and confirmatory trials remain warranted.
ESG summaryEndoscopic Sleeve Gastroplasty (ESG) uses endoscopic suturing devices (e.g., OverStitch) to reduce gastric volume transorally without resection.
Place in therapyESG is an emerging minimally invasive alternative that has shown greater weight loss than lifestyle modification in trials but requires more long‑term comparative data versus surgical sleeve gastrectomy.
Device exampleOverStitch is a commonly used endoscopic suturing platform for ESG procedures described in the literature.
DefinitionVagus nerve blocking (vBloc/Maestro) is an implanted neuroregulator that delivers intermittent vagal blockade to reduce appetite and modify satiety signals.
RCT outcomesRandomized trials (ReCharge) showed mixed efficacy: some improvements versus sham but prespecified coprimary efficacy endpoints were not met in pivotal analyses; longer‑term durability data are limited.
Safety noteCommon AEs include heartburn/dyspepsia and implant site pain; reported primary related serious AE rate ~4.3% in ReCharge follow‑up reports.
inv-98: Gastrointestinal liner (EndoBarrier/DJBL) — definition and associated risks
DefinitionGastrointestinal liner (EndoBarrier/DJBL) is an endoscopically placed duodenal‑jejunal bypass sleeve that lines the proximal small intestine to alter nutrient contact and metabolic signaling.
Associated risksStudies report high rates of adverse events including GI hemorrhage, device obstruction, and hepatic abscess; many patients experience weight regain after explantation.
Evidence statusEvidence shows weight and metabolic improvements while in place but safety concerns and frequent early explantations limit routine use; NICE recommends use only in research and notes loss of CE mark for some devices.
inv-99: Intragastric Balloon (IGB) — Orbera and temporary device description
Orbera/temporary deviceOrbera is an FDA‑approved endoscopically placed intragastric balloon indicated as an adjunct for adults with BMI ≥30 and ≤40 kg/m² for up to six months, used with supervised diet and behavior modification.
Device purposeTemporary intragastric balloons induce weight loss while in place; long‑term maintenance after removal requires ongoing lifestyle and follow‑up interventions.
Safety and follow-upASMBS and ASGE guidance emphasize patient counseling on early tolerance symptoms, timely removal to avoid complications, and mechanisms for long‑term follow‑up to maintain weight loss.
DJBL definitionDuodenal‑jejunal bypass liner (DJBL/EndoBarrier) is an endoscopically implanted sleeve lining the proximal small intestine to alter nutrient contact and metabolic signaling.
Evidence summaryRCTs and observational studies show weight and metabolic improvements while device is implanted but substantial rates of adverse events, early explantation, and weight regain after removal have been reported; NICE recommends use only in research.
Regulatory noteThe device has had CE‑mark status changes and is not currently approved for broad use in some jurisdictions; research context is emphasized.
inv-101: Adolescent MBS eligibility — BMI thresholds per societies
ASMBS adolescent BMI criteriaASMBS pediatric guideline: BMI ≥120% of 95th percentile with a comorbidity, or ≥140% of 95th percentile (or absolute BMI cutoffs 35–39.9 and ≥40 kg/m² respectively) for adolescent MBS consideration.
AAP age and thresholdsAAP (2023) recommends consideration of MBS for patients ≥12 years with Class II (BMI ≥35 or 120% of 95th percentile) with clinically significant disease, and Class III (BMI ≥40 or 140% of 95th percentile).
Endocrine Society conditionsEndocrine Society recommends surgery in Tanner 4–5 adolescents meeting BMI criteria with significant comorbidities and with psychosocial/family stability and access to experienced pediatric centers.
inv-102: Lower BMI threshold for certain ethnic groups — NICE adjustment recommendations
NICE ethnicity adjustmentNICE suggests reducing BMI thresholds by 2.5 kg/m² for South Asian, Chinese, other Asian, Middle Eastern, Black African or African‑Caribbean backgrounds to account for higher cardiometabolic risk at lower BMI.
ADA ethnicity guidanceADA recommends consideration of lower BMI thresholds for Asian individuals (e.g., consider metabolic surgery at BMI ≥27.5 or adjust thresholds by ~2.5 kg/m²).
Clinical implicationApply ethnicity‑specific BMI adjustments when assessing eligibility for metabolic/bariatric interventions per guideline recommendations.
inv-103: ORBERA Intragastric Balloon System — FDA-approved indication summary
ORBERA FDA indicationORBERA Intragastric Balloon System is FDA‑approved as an adjunct to weight reduction for adults with BMI ≥30 and ≤40 kg/m² for up to six months, used with supervised diet and behavior modification.
Placement durationMaximum placement period for ORBERA is six months per FDA approval and device labeling.
Candidate requirementsIndicated for adults who have failed conservative weight‑reduction strategies and agree to multidisciplinary follow‑up per FDA PMA summary.
inv-104: InterQual — reference to InterQual criteria source
InterQual as criteria sourceUnitedHealthcare references InterQual clinical practice (Procedures: Bariatric or Metabolic Surgery and Bariatric or Metabolic Surgery - Adolescent) for medical necessity determinations.
Provider action implicationPrior authorization and medical necessity decisions should refer to InterQual criteria for specific inclusion/exclusion details.
Documentation noteClaims and authorizations should use the specified CPT codes and align with InterQual guidance where applicable.